



## Agenda & Speakers:

11:30AM-12:00PM  
Registration & Lunch

12:00-12:10PM  
Welcome Remarks  
*Øystein Soug, CEO, Targovax*

12:10-12:50PM  
Oncolytic Virus Overview and Q&A  
*Dmitriy Zamarin, MD, PhD*

12:50-1:30PM  
Melanoma: the disease, CPIs, and lack of treatment options; Early ONCOS-102 data  
*Alexander N. Shoushtari, MD*

1:30-1:50PM  
Mesothelioma ORR Data  
*Magnus Jaderberg, CMO, Targovax*

1:50-2:00PM  
Closing Remarks  
*Øystein Soug, CEO, Targovax*

## PLEASE JOIN US FOR A KOL EVENT

Leading experts discuss the oncolytic virus landscape and present interim data from Targovax's ongoing melanoma and mesothelioma trials

DATE		Thursday, October 11th, 2018
TIME		11:30 AM EST
LOCATION		The Maxwell (formerly The W Hotel) 541 Lexington Avenue, Great Room 1

## KOL PARTICIPANTS:

**Dmitriy Zamarin, MD, PhD**  
Medical Oncologist, Memorial Sloan Kettering

**Alexander N. Shoushtari, MD**  
Medical Oncologist, Melanoma, Memorial Sloan Kettering

# Important NOTICE AND DISCLAIMER

This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.

There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and know-how; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's products; risks that research and development will not yield new products that achieve commercial success; risks relating to the company's ability to successfully commercialize and gain market acceptance for Targovax's products; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks associated with technological development, growth management, general economic and business conditions; risks relating to the company's ability to retain key personnel; and risks relating to the impact of competition.






# 1

## Introduction


2. Oncolytic virus overview – Dr. Dmitriy Zamarin
3. ONCOS-102 in melanoma – Dr. Alexander Shoushtari
4. ONCOS-102 in mesothelioma – Dr. Magnus Jäderberg
5. Summary & closing

# TARGOVAX AIM IS TO ACTIVATE THE PATIENT'S OWN IMMUNE SYSTEM TO FIGHT CANCER

Targovax focus




Targovax has two programs in clinical development, with an  
**ONCOLYTIC VIRUS LEAD PRODUCT CANDIDATE**



**ONCOS**  
Oncolytic virus

**Lead product candidate**

- Genetically **armed adenovirus**
- **Alerts the immune system** to the presence of cancer antigens
- **Induces T-cells** specific to the patients' tumor
- **4 ongoing trials**



**TG**  
Neoantigen  
vaccine

**Pipeline product**


- **Shared neoantigen**, therapeutic cancer vaccine
- Triggers the immune system to **recognize mutant RAS cancers**

*Activates the  
immune system*

*Triggers patient-  
specific responses*

*No need for  
individualization*

# ONCOS-102 is a cancer targeting adenovirus armed with an **IMMUNE STIMULATING TRANSGENE**



# ONCOS-102

Phase I proof of concept

## IMMUNE ACTIVATION DEMONSTRATED

### ONCOS-102 Phase I trial design:


- 12 patients, 7 different solid tumors
- No other treatment options left
- Monotherapy 9 injections

### Top-line results:

- 100% innate immune activation
- 11/12 patients increase in TILs
- Abscopal effect
- Tumor specific T-cells in blood
- Correlation with survival

### Cold tumor turned hot

CD8+ T-cell staining



Pre-treatment

Post-treatment


# ONCOS-102

Phase I single agent proof of concept

## CD8+ T-CELL INFILTRATION CORRELATES WITH SURVIVAL

Fold-change CD8+ T-cell count vs. survival

$r = 0.75$   $p = 0.005$



### Case example

- Ovarian cancer
- Failed on 5 chemotherapies
- Tumor specific T-cells after 2 years
- Stable disease for 3 years
- Survived 3.5 years



# ONCOS

## CLINICAL PROGRAM OVERVIEW

